elasnin: elastase inhibitor isolated from Streptomyces noboritoensis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 54685126 |
| CHEMBL ID | 54524 |
| SCHEMBL ID | 4287894 |
| MeSH ID | M0068957 |
| Synonym |
|---|
| elasnin |
| brn 1265379 |
| 3,5-dibutyl-6-(1-butyl-2-oxoheptyl)-4-hydroxy-2h-pyran-2-one |
| 2h-pyran-2-one, 3,5-dibutyl-6-(1-butyl-2-oxoheptyl)-4-hydroxy- |
| CHEMBL54524 , |
| 68112-21-0 |
| 3,5-dibutyl-2-hydroxy-6-(6-oxoundecan-5-yl)-4h-pyran-4-one |
| bdbm50405203 |
| 5-18-03-00063 (beilstein handbook reference) |
| SCHEMBL4287894 |
| 3,5-dibutyl-4-hydroxy-6-(6-oxoundecan-5-yl)-2h-pyran-2-one |
| HB3885 |
| DTXSID00987589 |
| 3,5-dibutyl-4-hydroxy-6-(6-oxoundecan-5-yl)pyran-2-one |
| CS-0086907 |
| HY-124556 |
| AKOS040748312 |
Elasnin is a recently reported antibiofilm agent that is effective against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) Elasnin exhibits high efficiency in inhibiting marine biofilms and biofouling.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Elasnin is a recently reported antibiofilm agent that is effective against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). " | ( Elasnin Effectively Eradicates Daptomycin-Resistant Methicillin-Resistant Staphylococcus aureus Biofilms. Lam, H; Long, L; Qian, PY; Sulaiman, JE, 2022) | 3.61 |
| "Elasnin is a potent antibiofilm compound that exhibits high efficiency in inhibiting marine biofilms and biofouling, but its mode of action remains unclear." | ( Mechanistic Insight into the Inhibitory Activity of Elasnin-Based Coating against Early Marine Biofilms. Chen, F; Huang, Y; Lam, H; Long, L; Luo, F; Qian, PY; Sulaiman, JE; Tang, JW; Wong, W; Wu, C; Wu, L; Xiao, Y, 2023) | 1.88 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Neutrophil elastase | Homo sapiens (human) | Ki | 93.3254 | 0.0020 | 1.2866 | 9.5499 | AID66470 |
| Chymotrypsin-C | Homo sapiens (human) | Ki | 223.8720 | 0.0010 | 0.9240 | 3.7000 | AID52466 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| protease binding | Neutrophil elastase | Homo sapiens (human) |
| transcription corepressor activity | Neutrophil elastase | Homo sapiens (human) |
| endopeptidase activity | Neutrophil elastase | Homo sapiens (human) |
| serine-type endopeptidase activity | Neutrophil elastase | Homo sapiens (human) |
| protein binding | Neutrophil elastase | Homo sapiens (human) |
| heparin binding | Neutrophil elastase | Homo sapiens (human) |
| peptidase activity | Neutrophil elastase | Homo sapiens (human) |
| cytokine binding | Neutrophil elastase | Homo sapiens (human) |
| protein binding | Chymotrypsin-C | Homo sapiens (human) |
| peptidase activity | Chymotrypsin-C | Homo sapiens (human) |
| serine-type endopeptidase activity | Chymotrypsin-C | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Neutrophil elastase | Homo sapiens (human) |
| extracellular space | Neutrophil elastase | Homo sapiens (human) |
| cytoplasm | Neutrophil elastase | Homo sapiens (human) |
| cytosol | Neutrophil elastase | Homo sapiens (human) |
| cell surface | Neutrophil elastase | Homo sapiens (human) |
| secretory granule | Neutrophil elastase | Homo sapiens (human) |
| azurophil granule lumen | Neutrophil elastase | Homo sapiens (human) |
| specific granule lumen | Neutrophil elastase | Homo sapiens (human) |
| phagocytic vesicle | Neutrophil elastase | Homo sapiens (human) |
| collagen-containing extracellular matrix | Neutrophil elastase | Homo sapiens (human) |
| extracellular exosome | Neutrophil elastase | Homo sapiens (human) |
| transcription repressor complex | Neutrophil elastase | Homo sapiens (human) |
| extracellular space | Neutrophil elastase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID66470 | Inhibitory activity against human leukocyte elastase (HL elastase) expressed as inhibitory constant | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | Inhibition of human leukocyte elastase, porcine pancreatic elastase, and chymotrypsin by elasnin and other 4-hydroxy-2-pyrones. |
| AID52466 | Inhibitory activity against bovine Chymotrypsinogen expressed as inhibitory constant | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | Inhibition of human leukocyte elastase, porcine pancreatic elastase, and chymotrypsin by elasnin and other 4-hydroxy-2-pyrones. |
| AID156214 | Inhibitory activity against porcine pancreatic elastase (PP elastase) expressed as inhibitory constant | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | Inhibition of human leukocyte elastase, porcine pancreatic elastase, and chymotrypsin by elasnin and other 4-hydroxy-2-pyrones. |
| AID19471 | Partition coefficient (logP) (octanol/saline) | 1985 | Journal of medicinal chemistry, Dec, Volume: 28, Issue:12 | Inhibition of human leukocyte elastase, porcine pancreatic elastase, and chymotrypsin by elasnin and other 4-hydroxy-2-pyrones. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.00) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||